Clinical Trials Logo

PR-Negative Breast Cancer clinical trials

View clinical trials related to PR-Negative Breast Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04504916 Completed - Pancreatic Cancer Clinical Trials

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)

Start date: October 7, 2020
Phase: Phase 2
Study type: Interventional

This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC HER2-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and platinum-resistant ovarian cancer. The study will evaluate a null hypothesis that the objective response rate (ORR) is ≤5% against the alternative hypothesis that it is ≥20%.